Download PDF
Klin Monbl Augenheilkd
DOI: 10.1055/a-2250-9841
Der interessante Fall

Recurrent Exposure of the PRESERFLO MicroShunt Implant

Wiederholte Exponierung des Preserflo Microshunt-Implantats
Lara Borrego Sanz 
1   Ocular Surface, Hospital Clínico San Carlos, Madrid, Spain
,
Carmen Dora Méndez Hernández 
2   Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain
,
Fernado Ly Yang
2   Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain
,
Verónica Gómez Calleja
3   Ophthalmology, Hospital Infanta Elena, Madrid, Spain
,
Federico Sáenz-Francés San Baldomero
2   Ophthalmology, Hospital Clínico San Carlos, Madrid, Spain
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Introduction

Over the last years, minimally invasive glaucoma surgery (MIGS) has emerged as a safer and less invasive surgical option compared to traditional filtering procedures for glaucoma treatment. The PRESERFLO MicroShunt (PM) – previously known as InnFocus MicroShunt – is a subconjunctival draining minimally invasive procedure, indicated for progressive mild to moderate open-angle glaucoma. Although adverse effects after its employment are not common, we report a case involving multiple recurrent exposures of the device, its management, and the possible risk factors related.



Publication History

Received: 18 October 2023

Accepted: 21 January 2024

Accepted Manuscript online:
22 January 2024

Article published online:
13 June 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Bunod R, Robin M, Buffault J. et al. PreserFlo MicroShunt exposure: a case series. BMC Ophthalmol 2021; 21: 273
    Search in Google Scholar
  • 2 Saeed E, Zalewska R, Konopińska J. Early Complications and Results of Preserflo MicroShunt in the Management of Uncontrolled Open-Angle Glaucoma: A Case Series. Int J Environ Res Public Health 2022; 19: 8679
    Search in Google Scholar
  • 3 DeBry PW, Perkins TW, Heatley G. et al. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol 2002; 120: 297-300
    Search in Google Scholar
  • 4 Beckers HJM, Aptel F, Webers CAB. et al. Safety and Effectiveness of the PRESERFLO MicroShunt in Primary Open-Angle Glaucoma: Results from a 2-Year Multicenter Study. Ophthalmol Glaucoma 2022; 5: 195-209
    Search in Google Scholar
  • 5 Scheres LMJ, Kujovic-Aleksov S, Ramdas WD. et al. XEN Gel Stent compared to PRESERFLO MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol 2021; 99: e433-e440
    Search in Google Scholar
  • 6 Al-Beishri AS, Malik R, Freidi A. et al. Risk Factors for Glaucoma Drainage Device Exposure in a Middle-Eastern Population. J Glaucoma 2019; 28: 529-534
    Search in Google Scholar
  • 7 Koval MS, El Sayyad FF, Bell NP. et al. Risk factors for tube shunt exposure: a matched case-control study. J Ophthalmol 2013; 2013: 196215
    Search in Google Scholar
  • 8 Baudouin C, Pisella PJ, Fillacier K. et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs. Ophthalmology 1999; 106: 556-563
    Search in Google Scholar
  • 9 Arnould L, Theillac V, Moran S. et al. Recurrent Exposure of XEN Gel Stent Implant and Conjunctival Erosion. J Glaucoma 2019; 28: e37-e40
    Search in Google Scholar
  • 10 Rosentreter A, Lappas A, Widder RA. et al. Conjunctival repair after glaucoma drainage device exposure using collagen-glycosaminoglycane matrices. BMC Ophthalmol 2018; 18: 60
    Search in Google Scholar